NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
National Guideline Alliance (UK). Cystic Fibrosis: Diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2017 Oct 25. (NICE Guideline, No. 78.)
All Committee members’ interests were recorded on declaration forms provided by NICE. The form covered personal, non-personal, specific or non-specific and non-financial or financial declarations. Committee members’ declarations of interests are listed in this section. No conflicts were identified that required a Committee member to be asked not to participate in the relevant discussions. Details are available from the Committee minutes available on the NICE website where the policy can also be accessed (see https://www.nice.org.uk/about/who-we-are/policies-and-procedures).
This appendix includes all interests declared between the start of development and submission on 4th October 2017.
Name | Job title, organisation | Declarations of Interest, date declared | Type of interest | Decision taken |
---|---|---|---|---|
Mandy Bryon | Consultant Clinical Psychologist and Joint Head of Paediatric Psychology and Play Services, Great Ormond Street Hospital Foundation Trust | Member of the UK Heads of Paediatric Psychology Special Interest Group 03/03/2015 | Personal non-financial, non-specific | Declare and participate |
Mandy Bryon | Consultant Clinical Psychologist and Joint Head of Paediatric Psychology and Play Services, Great Ormond Street Hospital Foundation Trust | Co-Chair of the UK Psychosocial Professionals in a Cystic Fibrosis group sponsored by Forest Pharmaceuticals and a committee member of the Cystic Fibrosis Trust Clinical Advisory Group, the Cystic Fibrosis trust Peer review Oversight Board and the European Cystic Fibrosis Special Interest Group (term of office ending June 2014) 03/03/2015 | Personal non-financial, specific | Declare and participate |
Mandy Bryon | Consultant Clinical Psychologist and Joint Head of Paediatric Psychology and Play Services, Great Ormond Street Hospital Foundation Trust | Registered stakeholders of the Clinical Reference Groups for Cystic Fibrosis 03/03/2015 | Personal non-financial, specific | Declare and participate |
Mandy Bryon | Consultant Clinical Psychologist and Joint Head of Paediatric Psychology and Play Services, Great Ormond Street Hospital Foundation Trust | Published 5 articles related to Cystic Fibrosis: Bryon, M, Havermans, T, Noordhoek, J. (2012) The social life of adolescents with cystic fibrosis. Healthcare issues and Challenges in Adolescents with Cystic Fibrosis. C. Castellani, S Elborn, H Heijerman (eds). European Cystic Fibrosis Society, Karup: Denmark. Randlesome, K, Bryon M, Evangeli, M (2013) Developing a measure of eating attitudes and behaviours in cystic fibrosis Journal of Cystic Fibrosis 12; 15 – 21. Alan R. Smyth, Scott C. Bell, Snezana Bojcin, Mandy Bryon, Alistair Duff, Patrick Flume, Nataliya Kashirskaya, Anne Munck, Felix Ratjen, Sarah Jane Schwarzenberg, Isabelle Sermet-Gaudelus, Kevin W. Southern, Giovanni Taccetti, Gerald Ullrich, Sue Wolfe. (2014) European Cystic Fibrosis Society Standards of Care: Best Practice guidelines, Journal of Cystic Fibrosis 13 (2014) S23–S42. A Kevin Webb, Mandy Bryon (2014) The International Depression Epidemiological Study (TIDES): unfinished business? Thorax 2014. Bryon, M (2015) Eating Disorders and Disturbed Eating Attitudes and Behaviours Typical in CF. In Watson RR, Diet and Exercise in Cystic Fibrosis, Elsevier, San Diego, CA. p69–72. 03/03/2015 | Personal non-financial, specific | Declare and participate (none of these are covered as part of the guideline scope) |
Mandy Bryon | Consultant Clinical Psychologist and Joint Head of Paediatric Psychology and Play Services, Great Ormond Street Hospital Foundation Trust | Speaker at a meeting arranged by CF Ireland about psychological issues for parents of children and young people with Cystic Fibrosis. The title of the presentation was “Family Matters – finding the balance with CF”. No personal fees received but CF Ireland paid for travel and overnight expenses. 21/04/2015 | Personal financial, non-specific | Declare and participate |
Mandy Bryon | Consultant Clinical Psychologist and Joint Head of Paediatric Psychology and Play Services, Great Ormond Street Hospital Foundation Trust | Speaker at Cystic Fibrosis conference on ‘Bridging the gap between standards of care and clinical provision of psychology’. 21/04/2015 | Personal non-financial, non-specific This is non-specific as this is not discussed in this guideline. | Declare and participate (not covered as part of the guideline scope) |
Mandy Bryon | Consultant Clinical Psychologist and Joint Head of Paediatric Psychology and Play Services, Great Ormond Street Hospital Foundation Trust | Attended dinner sponsored by Actavis pharmaceuticals at the European Cystic Fibrosis conference. No sponsorship received, just dinners out with the rest of the CF team from these pharmaceutical companies. 03/06/2015 | Personal non-financial, non-specific | Declare and participate (expenses within NICE policy) |
Mandy Bryon | Consultant Clinical Psychologist and Joint Head of Paediatric Psychology and Play Services, Great Ormond Street Hospital Foundation Trust | Invited speaker at the UK Cystic Fibrosis conference organised by the Cystic Fibrosis Trust. This was the annual CF conference arranged by the CF Trust. My presentation was: CF adolescence is no different from non-CF adolescence. Travel and overnight expenses paid but no fees received. 31/09/2015 | Personal non-financial, specific | Declare and participate |
Mandy Bryon | Consultant Clinical Psychologist and Joint Head of Paediatric Psychology and Play Services, Great Ormond Street Hospital Foundation Trust | Attended meeting to discuss the desire and feasibility of establishing a Cystic Fibrosis Society for health professionals. 31/09/2015 | Personal non-financial, non-specific | Declare and participate |
Mandy Bryon | Consultant Clinical Psychologist and Joint Head of Paediatric Psychology and Play Services, Great Ormond Street Hospital Foundation Trust | Invited speaker at a Cystic Fibrosis conference to present on the topic of mental health (how the impact of knowing a person has an incurable life-threatening disease might affect their mental health) and Cystic Fibrosis. No fees received. 01/03/2016 | Personal, non-financial, non-specific | Declare and participate (not covered as part of the guideline scope) |
Mandy Bryon | Consultant Clinical Psychologist and Joint Head of Paediatric Psychology and Play Services, Great Ormond Street Hospital Foundation Trust | Attended a conference titled “Cystic Fibrosis Masterclass” on 20th May. Expenses for travel and overnight expenses, dinner and time spent on slide preparation sponsored by Vertex as an invited speaker. The topic of the presentation was “The psychological and developmental complexities that make adherence so challenging” 15/06/2016 | Personal financial, specific | Declare and participate [as ivacaftor and lumacaftor are outside of the scope of the guideline (Vertex is the manufacturer)] |
Mandy Bryon | Consultant Clinical Psychologist and Joint Head of Paediatric Psychology and Play Services, Great Ormond Street Hospital Foundation Trust | Attended the European CF conference from 8th – 11th June. Attended two dinners with CF team and other CF teams from the UK. One meal was sponsored by Acativs Allergan and one sponsored by Chiesi. No personal sponsorship received, just dinners out with the rest of the CF team from these pharmaceutical companies. No personal finance was received. 15/06/2016 | Personal non-financial, specific | Declare and participate (expenses within NICE policy) |
Mandy Byron | Consultant Clinical Psychologist and Joint Head of Paediatric Psychology and Play Services, Great Ormond Street Hospital Foundation Trust | Attended an advisory group on 14th November 2016 to advise on the development of an adherence training programme for CF professionals. The training programme is being developed by Hammel, behaviour change consultants but the meeting was sponsored by Chiesi. I was given an attendance fee but not travel or other expenses. Advice from NICE was sought before attending this meeting and their guidance was followed. I am prepared to sit out of any future meeting where drugs produced by Chiesi are discussed. 23/11/2016 | Personal financial, non-specific | Advice taken from NICE - Declare and withdraw from future discussions regarding tobramycin and hypertonic saline. |
Mandy Byron | Consultant Clinical Psychologist and Joint Head of Paediatric Psychology and Play Services, Great Ormond Street Hospital Foundation Trust | Attended a study day at the Royal Society of Medicine on 15th November 2015 on Cystic Fibrosis in children and adults. I was not a speaker and received no fees or expenses for attending but the fee to attend the day was subsidised for all attendees by an unrestricted educational grant to the RSM from Teva pharmaceuticals. 11/01/2017 | Non-personal financial, non-specific | Declare and participate |
Mandy Byron | Consultant Clinical Psychologist and Joint Head of Paediatric Psychology and Play Services, Great Ormond Street Hospital Foundation Trust | I attended a committee meeting of the UK Psychosocial professionals in Cystic Fibrosis on 18th and 19th January 2017. The meeting was sponsored by the pharmaceutical company Teva. Travel expenses and overnight accommodation were paid for by Teva – within the agreed limits of NICE guidance. 08/02/2017 | Personal non-financial, non-specific | Declare and participate (hospitality within NICE policy) |
Mandy Byron | Consultant Clinical Psychologist and Joint Head of Paediatric Psychology and Play Services, Great Ormond Street Hospital Foundation Trust | I attended the European Cystic Fibrosis conference in June 2017 and attended a dinner sponsored by Chiesi pharmaceutical company. The dinner was attended by my CF team and various other CF teams from the UK as is normal practice at this annual conference. 05/07/2017 | Personal non-financial, non-specific | Declare and participate |
Janis Bloomer | Paediatric Nurse Specialist (Children and young people) Cystic Fibrosis, Great North Children’s Hospital Royal Victoria Infirmary | Current active member of UK Cystic Fibrosis Nurse Association 21/04/2015 | Personal non-financial specific An interest is ‘specific’ if it refers directly to the matter under discussion. Being an active member of this association does indicate a specific interest. | Declare and participate |
Janis Bloomer | Paediatric Nurse Specialist (Children and young people) Cystic Fibrosis, Great North Children’s Hospital Royal Victoria Infirmary | Accepted for European CF Conference in June 2015 Presenting poster re Telephone Triage Tool for reporting respiratory problems in children with CF. 21/04/2015 | Personal non-financial non-specific An interest is ‘non-specific’ if it does not refer directly to the matter under discussion. Telephone triage is not directly discussed in this guideline. | Declare and participate (as intervention not covered in scope) |
Sarah Collins | CF Specialist Dietitian, Nutrition & Dietetic Department, Royal Brompton Hospital | As a member of the Abott Advisory Panel on Pancreatic Exocrine Insufficiency, attended a one off meeting which was completed in her own time. This was a multidisciplinary advisory board about PERT, it was run by Abbott who at the time manufactured Creon preparations. It was about marketing, and image of the brand. Received £200. 03/03/2015 | Personal non-financial, specific | Declare and participate |
Sarah Collins | CF Specialist Dietitian, Nutrition & Dietetic Department, Royal Brompton Hospital | Chair of the UK Dietitians CF Interest Group. Due to stand down as chair in May 2016. 03/03/2015 | Personal non-financial, specific | Declare and participate |
Sarah Collins | CF Specialist Dietitian, Nutrition & Dietetic Department, Royal Brompton Hospital | Chair of UK Dietitians CF group who are writing a consensus document on the Nutritional management of CF This is a consensus document written by a group of professionals that has been published by the CF Trust. It covers all of the nutritional management of CF. In the document specific products are not recommended. 03/03/2015 | Personal non-financial, specific | Declare and participate |
Sarah Collins | CF Specialist Dietitian, Nutrition & Dietetic Department, Royal Brompton Hospital | Invited speaker at Paediatric Expert Summit in Dubai, sponsored by Abbott. The presentation was titled Nutritional management of CF. flights, transfers and accommodation provided and honorarium received. Completed in own time. 03/03/2015 | Personal financial, non-specific | Declare and participate (expenses within NICE policy) |
Sarah Collins | CF Specialist Dietitian, Nutrition & Dietetic Department, Royal Brompton Hospital | Attendance at the European Cystic Fibrosis meeting on Thursday 11th June 2015. Attended a hospitality event which was sponsored by Chiesi and Allergan. 19/08/2015 | Personal non-financial, non-specific The hospitality was within the NICE policy and therefore not considered financial, the meeting was general and not directly related to the content of the guideline = non-specific | Declare and participate (expenses hospitality within NICE policy) |
Sarah Collins | CF Specialist Dietitian, Nutrition & Dietetic Department, Royal Brompton Hospital | Invited to be a member of the James Lind Alliance’s Cystic Fibrosis Priority Setting Partnership (PSP) Steering Group, which is jointly funded by the UK CF Trust, the University of Nottingham and Nottingham Hospital NHS Trust Charity. 01/03/2016 | Personal non-financial, specific | Declare and participate |
Sarah Collins | CF Specialist Dietitian, Nutrition & Dietetic Department, Royal Brompton Hospital | Awarded a NIHR/HEE-ICA Clinical Doctoral Research Fellowship, based at Royal Brompton Hospital, registration for PhD at King’s College, London. Will be undertaking a training and research programme to obtain PhD, in addition to a clinical commitment. 26/04/2016 | Non-personal financial, non-specific This is nons-pecific as she has not started to undertake any research yet and therefore cannot state if the topics will be discussed in this guideline. | Declare and participate |
Sarah Collins | CF Specialist Dietitian, Nutrition & Dietetic Department, Royal Brompton Hospital | Attendance at the European Cystic Fibrosis meeting in June 2016. Attended a hospitality event which was sponsored by Chiesi and Allergan. 15/06/2016 | Personal non-financial, non-specific The hospitality was within the NICE policy and therefore not considered financial, the meeting was general and not directly related to the content of the guideline = non-specific | Declare and participate (expenses within NICE policy) |
Sarah Collins | CF Specialist Dietitian, Nutrition & Dietetic Department, Royal Brompton Hospital | I spoke at the RSM CF meeting on 15th November 2016. My talk was entitled the Nutritional Management of CF. I did not receive any financial reimbursement for this. 23/11/2016 | Personal non-financial, specific | Declare and participate |
Sarah Collins | CF Specialist Dietitian, Nutrition & Dietetic Department, Royal Brompton Hospital | I was an invited speaker at the European CF Conference 2017. I gave two talks, one on enteral tube feeding and the other on CFRD. The enteral feeding talk was part of a procon debate regarding if enteral feeding should be started earlier than it already is. The CFRD talk was on the nutritional management of CFRD. The ECFS paid for my travel to and from the conference and for my accommodation. 05/07/2017 | Personal non-financial, non-specific | Declare and participate |
Sarah Collins | CF Specialist Dietitian, Nutrition & Dietetic Department, Royal Brompton Hospital | At the European Cystic Fibrosis meeting on Thursday 8th June I attended a hospitality event (meal) with my team from Royal Brompton Hospital which was sponsored by Vertex. 05/07/2017 | Personal non-financial, non-specific | Declare and participate |
Alexander Darlington | Lay member | Undertaking a PhD studentship as part of the Synthetic Biology Centre for Doctoral Training, joint funded by the BBSRC (Biotechnology and Biological Sciences Research Council) and EPSRC (Engineering and Physical Sciences Research Council). Additional funding for the centre itself and its infrastructure is provided by Shell Global Solutions, GlaxoSmithKline, Microsoft, DSTL (Defence Science and Technology Laboratory), Crysalin, Proctor and Gamble, DNA2 and Syngenta. 03/03/2015 | Non-personal financial, non-specific Based on NICE policy: “A grant or fellowship or other payment to sponsor a post or member of staff in the unit where the individual is employed.” | Declare and participate |
Alexander Darlington | Lay member | Contributed to a paper due to be published in June 2015. The work was carried out in 2012 and was funded by the CF Trust. The paper was an investigation of the non-nervous innovation of secretions in the airways. In the long term this research could inform post-transplant lung care but that is mainly conjecture – it was simply a physiological/pharmac ological ‘basic science’ study on the airways of the sheep rather than a clinical study. 03/03/2015 | Personal non-financial, specific | Declare and participate |
Iolo Doull | Consultant Respiratory Paediatrician, Children’s Hospital for Wales, Cardiff | Lecture on childhood asthma for Novartis Educational. 03/03/2015 | Personal financial, non-specific | Declare and participate (Asthma is not discussed in this guideline) |
Iolo Doull | Consultant Respiratory Paediatrician, Children’s Hospital for Wales, Cardiff | Member of Gilead Advisory Panel (March 2014) to consider data on the use of nebulised aztreonam in CF. Honorarium was paid. 03/03/2015 | Personal financial, specific | Declare and participate (beyond 12 months before meeting where aztreonam was discussed) |
Iolo Doull | Consultant Respiratory Paediatrician, Children’s Hospital for Wales, Cardiff | President of the British Paediatric Respiratory Society 19/08/2015 | Personal non-financial, non-specific | Declare and participate |
Iolo Doull | Consultant Respiratory Paediatrician, Children’s Hospital for Wales, Cardiff | Trustee for ASH Wales 19/08/2015 | Personal non-financial, non-specific | Declare and participate |
Iolo Doull | Consultant Respiratory Paediatrician, Children’s Hospital for Wales, Cardiff | Organises the annual Royal Society of Medicine CF study day. The RSM receives an unrestricted educational grant from Actavis towards this meeting. 19/08/2015 | Non-personal financial, specific | Declare and participate |
Iolo Doull | Consultant Respiratory Paediatrician, Children’s Hospital for Wales, Cardiff | Member of the audit committee for the Children’s Commissioner for Wales and sits on the Cystic Fibrosis Trust Clinical Advisory Group and Registry Committee. 19/08/2015 | Personal non-financial, specific | Declare and participate |
Iolo Doull | Consultant Respiratory Paediatrician, Children’s Hospital for Wales, Cardiff | Educational lectures on asthma for Astra Zeneca Educational. 19/08/2015 | Personal financial, non-specific | Declare and participate (Asthma not discussed in this review) |
Iolo Doull | Consultant Respiratory Paediatrician, Children’s Hospital for Wales, Cardiff | Authored a paper that was considered and excluded as part of the Guideline review on models of care in CF - Full, shared and hybrid paediatric care for cystic fibrosis in South and Mid Wales. Doull I, Evans H; South and Mid Wales Paediatric Cystic Fibrosis Network. Arch Dis Child. 2012 Jan;97(1):17–20 26/04/2016 | Personal non-financial, specific | Declare and participate (This was published in 2012; therefore more than 12 months before he joined the committee) |
Iolo Doull | Consultant Respiratory Paediatrician, Children’s Hospital for Wales, Cardiff | Attended a meal funded by Actavis. 15/06/2016 | Personal financial, specific | Declare and participate (expenses within NICE policy) |
Iolo Doull | Consultant Respiratory Paediatrician, Children’s Hospital for Wales, Cardiff | Organised a meeting to establish a British Cystic Fibrosis Society at the European CF Society meeting. Actavis supplied funding for the room hire. 15/06/2016 | Non-personal financial, specific | Declare and participate (expenses within NICE policy) |
Iolo Doull | Consultant Respiratory Paediatrician, Children’s Hospital for Wales, Cardiff | Gave a talk to GPs about asthma which was sponsored by Astrazeneca. Was paid directly. Astrazeneca do not manufacture any products discussed in this guideline or for the treatment of CF. 19.10.2016 | Personal financial, non-specific | Declare and participate |
Iolo Doull | Consultant Respiratory Paediatrician, Children’s Hospital for Wales, Cardiff | I received payment from Astra Zeneca to give a lecture on Asthma in Childhood 23/11/2016 | Personal financial, non-specific | Declare and participate (Asthma is not discussed in this guideline) |
Iolo Doull | Consultant Respiratory Paediatrician, Children’s Hospital for Wales, Cardiff | I received payment to attend a meeting on asthma in childhood from Bohringer Ingelheim. 23/11/2016 | Personal financial, non-specific | Declare and participate (Asthma is not discussed in this guideline) |
Iolo Doull | Consultant Respiratory Paediatrician, Children’s Hospital for Wales, Cardiff | I attended a meeting on asthma in childhood where my meal was paid for by GSK 23/11/2016 | Personal non-financial, non-specific | Declare and participate (Asthma is not discussed in this guideline) |
Iolo Doull | Consultant Respiratory Paediatrician, Children’s Hospital for Wales, Cardiff | I have given an educational talk on wheeze and asthma in primary care for which I received a fee from Astra Zeneca. 05/07/2017 | Personal non-financial, non-specific | Declare and participate (Asthma is not discussed in this guideline) |
Iolo Doull | Consultant Respiratory Paediatrician, Children’s Hospital for Wales, Cardiff | Involved in recruitment for the de Boeck Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial in 2013. Payment was made to my health board. 26/07/2017 | Non-personal financial, specific | Declare and participate (mannitol is discussed in this guideline but this declaration is non-personal financial) |
Elaine Edwards | Advanced Physiotherapist, Sheffield Children’s NHS Foundation Trust | Through the Association of Chartered Physiotherapists (ACPCF) contributed to the update of the Standards of care and good clinical practice for the physiotherapy management of Cystic Fibrosis, specifically the use of Non-invasive ventilation in Cystic Fibrosis and the use of Intermittent Positive Pressure breathing in Physiotherapy. 19/08/2015 | Personal non-financial, specific | Declare and participate |
Elaine Edwards | Advanced Physiotherapist, Sheffield Children’s NHS Foundation Trust | Works on the Cystic Fibrosis unit at Sheffield Children’s Hospital and has recruited patients to the following two studies (she is not active in either study and will only see patients in professional capacity): PEOteKT – phase 11a, randomised controlled open label trial of Rosuvastatin for the prevention of Aminoglycosideinduced kidney toxicity in children with Cystic Fibrosis. Vertex study. A phase 3 randomized double blind placebo controlled, parallel group study to evaluate the efficacy and safety of VX-661 in combination with Ivacaftor in subjects aged 12 years and older with CF, homozygous for the F508del-CFTR mutation. 31/09/2015 | Non-personal financial, specific | Declare and participate |
Elaine Edwards | Advanced Physiotherapist, Sheffield Children’s NHS Foundation Trust | Attended the Association of Physiotherapists in Cystic Fibrosis (ACPCF) annual study days. Travel fees were reimbursed by Actavis UK Ltd 01/03/2016 | Personal non-financial, specific | Declare and participate (expenses within NICE policy) |
Elaine Edwards | Advanced Physiotherapist, Sheffield Children’s NHS Foundation Trust | Helped organise, but not teach, a course on ‘Paediatric respiratory assessment and treatment for physiotherapists’ held by the Respiratory Physiotherapy team at Sheffield Children’s Hospital sponsored by Hill-Rom and B&D Electromedical (paid for lunch and consumables for course participants). Did not receive any personal financial gain. 20/07/2016 | Personal non-financial, specific | Declare and participate. |
Elaine Edwards | Advanced Physiotherapist, Sheffield Children’s NHS Foundation Trust | On the 21/9/16 attended a network meeting for the hospitals that form the network for Sheffield Children’s Foundation Hospital Cystic Fibrosis service. The venue and lunch was paid for using sponsorship from the drug company Vertex. None of the company’s representatives were present during the meeting times and they had no input into the agenda items discussed. 11/01/2017 | Personal non-financial, non-specific | Declare and participate (hospitality within NICE Policy) |
Elaine Edwards | Advanced Physiotherapist, Sheffield Children’s NHS Foundation Trust | I am the 3rd author on a piece of work about the use of text messages to try and help nebuliser compliance that has been accepted for publication in “Patient Preference and Adherence”. It was presented as an oral presentation at the ECFS conference in Basel, Switzerland in June 2016. It was submitted but rejected by the Journal of Cystic Fibrosis in June 2016 and the Journal of Telemedicine and Telecare in 2016. I have not personally and the Trust has not received any financial gain in relation to the piece of work. I have attached a copy of the abstract. 08/0/2017 | Personal non-financial, non-specific | Declare and participate |
Elaine Edwards | Advanced Physiotherapist, Sheffield Children’s NHS Foundation Trust | Attended South Yorkshire paediatric CF Network meeting on 09/03/2017. This was sponsored by PTC Therapeutics & Profle Pharma, Sponsorship covered refreshments and room hire. Neither company were involved in the formation of the agenda. 05/07/2017 | Non-personal non-financial, non-specific | |
Elaine Edwards | Advanced Physiotherapist, Sheffield Children’s NHS Foundation Trust | One of the authors on three posters that were presented at the ECF conference in Seville in June 2017. The titles wer: Successful administration of patient activation measure (PAMI) to caregivers of children with cystic fibrosis Are cystic fibrosis health professionals able to assess patient activation measures (PAMI) in parents of children with CF? Practicing what we preach – the value of team members trying cystic fibrosis treatment regimes. 05/07/2017 | Personal non-financial, non-specific | |
Stuart Elborn | Dean, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University, Belfast | Provide ongoing consultancy on clinical trial design and leadership for Vertex, Novartis, Gilead, Celtaxsys, Abbvie/Galapagos. All drugs are in development so there is no overlap with this guideline. 15/06/2016 | Personal financial, specific | Declare and participate (is a co-opted expert to the guideline and there is no overlap between the content of the guideline and the consultancy provided) |
Stuart Elborn | Dean, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University, Belfast | Lead for clinical trials with Vertex, Novartis and Celtaxsys, ProQr and Flatley Laboratories. This is ongoing. 15/06/2016 | Personal non-financial, specific | Declare and participate (is a co-opted expert to the guideline) |
Stuart Elborn | Dean, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University, Belfast | BBC interview on new data on Orkambi. No financial transaction involved. 23/11/2016 | Personal non-financial, specific | Declare and participate – (as a co-opted member) |
Zoe Elliott | Lay member | Member of the Cystic Fibrosis Trust’s Strategic Implementation Board, a lay advisory group for research for patient benefit trial and the Cystic Fibrosis Trust’s disbanded Principle Advisory Group. No payment for any of the roles received. The research for patient benefit trial is trialling a hearing test for those on IV aminoglycosides which doesn’t finish for at least another two years and isn’t an area covered by the guideline. My role on the Strategy Implementation Board has me giving my opinion on proposed research to be funded by the trust. The executive then decide whether to fund. I have no further involvement in that research. 03/03/2015 | Personal non-financial, specific | Declare and participate |
Zoe Elliott | Lay member | Lay reviewer for the Cochrane Cystic Fibrosis and Genetic Disorders group. 03/03/2015 | Personal non-financial, specific | Declare and participate |
Zoe Elliott | Lay member | Using the anonymity of the Cystic Fibrosis Aware twitter account tweeting opinions of the price of the Vertex drug Orkambi. 19/08/2015 | Personal non-financial, specific | Declare and participate |
Zoe Elliott | Lay member | Attendance at a dinner with the CF Trust. 31/09/2015 | Personal non-financial, non-specific | Declare and participate (hospitality and expenses were in line with the NHS policy, CF Trust is not a commercial body) |
Zoe Elliott | Lay member | Parent member of the James Lind Alliance Priority Setting Partnership in CF Steering Committee. I receive no payment for this. The steering committee is overseeing the project to ensure that as many community members as possible get involved and have their say over what they feel should be researched about the treatment and management of the condition. The end of the project will see the ten most popular questions being published, these may or may not become actual research projects in the future. | Personal non-financial, specific | Declare and participate |
Zoe Elliott | Lay member | Spoke at the CF Trust conference in September. The event was sponsored by: Vertex; Mylan; Pari Medical Ltd; Raptor Pharmaceuticals; PTC Therapeutics, Inc; Gilead Sciences; Concert Pharmaceuticals; Galapagos; SPS No payment or financial inducement for speaking at the event. 12/09/2016 | Non-personal, non-financial, non-specific | Declare and participate |
Zoe Elliott | Lay member | I have been paid for the communication & marketing work I did for the James Lind Alliance Priority Setting Partnership in Cystic Fibrosis. 08/02/2017 | Personal financial, non-specific | Declare and participate |
Zoe Elliott | Lay member | I am attending the EURORDIS Expert Patient and Researcher summer school in Barcelona. This is funded by the charity with help from the European Medicines Agency; the health programme of the European Union; Malalties Minoritaries http://www [01.06.2017] | Personal financial, non-specific | Declare and participate |
Zoe Elliott | Lay member | Accepted for European CF Conference June 2017 Presenting posters: #questionCF - The use of social media to engage the CF community in research Question CF: A James Lind Alliance Priority Setting Partnership in Cystic Fibrosis [31.03.2017] | Personal non-financial, non-specific | Declare and participate |
Zoe Elliott | Lay member | Provided a general quote to the CF Trust about why her twins participate in trials which has been used on the CF Trust information webpage about the CF Start trial. [30.06.2017] | Personal non-financial, non-specific | Declare and participate |
Zoe Elliott | Lay member | I am attending the EURORDIS Expert Patient and Researcher summer school in Barcelona. This is funded by the charity with help from the European Medicines Agency; the health programme of the European Union; Malalties Minoritaries http://www 05/07/2017 | Personal non-financial, non-specific | Declare and participate |
Zoe Elliott | Lay member | Accepted for European CF Conference June 2017 Presenting posters: #questionCF - The use of social media to engage the CF community in research Question CF: A James Lind Alliance Priority Setting Partnership in Cystic Fibrosis 05/07/2017 | Personal non-financial, non-specific | Declare and participate |
Zoe Elliott | Lay member | I am being paid to manage the website and social media accounts for the charity Cystic Fibrosis Care. 05/07/2017 | Personal financial, non-specific | Declare and participate |
Zoe Elliott | Lay member | Provided a general quote to the CF Trust about why her twins participate in trials which has been used on the CF Trust information webpage about the CF Start trial. 05/07/2017 | Personal non-financial, non-specific | Declare and participate |
Zoe Elliott | Lay member | I am presenting on the parents perspective of participating in clinical trials at the UK cystic fibrosis conference, I am not receiving payment for this. 30/08/2017 | Personal non-financial, non-specific | Declare and participate |
Zoe Elliott | Lay member | I am presenting on the parents perspective of adherence and treatment burden at the European Respiratory Society Congress in Milan. I am receiving a bursary of €600 to cover the costs of flights, accommodation and meals. | Personal financial, non-specific | Declare and participate |
Stephen Holden | Consultant Medical Microbiologist Nottingham University Hospitals NHS Trust | Received a one-off payment from Astellas Pharma for chairing an education meeting relating to Clostridium difficile infection. 31/09/2015 | Personal financial, non-specific | Declare and participate (coopted expert) Declare and participate |
Stephen Holden | Consultant Medical Microbiologist Nottingham University Hospitals NHS Trust | Ongoing consultancy with Profile Pharma. Advisory role limited to matters relating to the introduction of a UK licensed formulation of oral fosfomycin for the treatment of uncomplicated urinary tract infection. Profile Pharma also market Promixin for intravenous and nebulised use – these drugs are used in the management of cystic fibrosis but the work for the company does not relate to these products. 31/09/2015 | Personal financial, non-specific | Declare and participate (co-opted expert) |
Andrew Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | Sponsorship from Forest Pharmaceuticals (Actavis) for CF Centre’s annual away day team meeting and annual meeting with paediatric teams. Forrest hired the room for the meeting, this was done directly by Forrest (Actavis) and the conference facility and included basic refreshments for all participants, no other payment was received either by myself or the department. 03/03/2015 | Non-personal financial, specific This was sponsorship benefited to a department (the CF Centre’s team away day) in which the individual is employed but which is not received personally. It is specific as it was the CF Centre’s team away day and annual meeting. | Declare and participate |
Andrew Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | Participated in a multicentre project (2013–2015) evaluating clinical outcome of use of nebulised Aztreonam - this project is sponsored by Gilead Sciences. Gilead sponsored meeting venues and travel to meetings. 03/03/2015 | Personal financial, specific | Declare and participate (expenses within NICE policy; held more than 12 months before meeting where Aztreonam was discussed) |
Andrew Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | Speaker at the National Irish CF Meeting sponsored by Novartis. Travel expenses and accommodation were covered by Novartis who provide an unrestricted educational grant to sponsor the meeting, all my travel and accommodation was arranged by the meeting organisers, no other payment was received either by myself or the department. It was a general CF educational meeting. 03/03/2015 | Non-personal financial, specific | Declare and participate (expenses within NICE policy) |
Andrew Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | Trustee of the UK Cystic Fibrosis Trust. 03/03/2015 | Personal non-financial, specific | Declare and participate |
Andrew Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | On behalf of the Cystic Fibrosis Foundation Therapeutics Development Network Data Safety Monitoring Board, conducted the Data Safety Monitoring of a Phase 2 study on the investigation of an anti-inflammatory product produced by Corbus. 03/06/2015 | Personal non-financial, specific | Declare and participate (not part of scope of guideline) |
Andrew Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | Delegate at the regional Transpennine CF Club meeting held on 25th February 2016. This meeting received sponsorship from Actavis UK Ltd. It was a free to attend educational meeting sponsored by Actavis. 19/08/2015 | Personal non-financial, specific | Declare and participate |
Andrew Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | Member of Cystic Fibrosis Trust Research Strategy Implementation Board (2013-January 2015). There are no areas of overlap between this role and the work on the guideline. 04/11/2015 | Personal non-financial, specific | Declare and participate |
Andrew Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | Chair (2004-) of the Cystic Fibrosis Trust Infection Control Committee. This committee has published national recommendations for the prevention and control of Pseudomonas aeruginosa infection (2001 and 2004), Burkholderia cepacia complex infection (2004), MRSA (2010) and (M. abscessus 2013) in people with cystic fibrosis 04/11/2015 | Personal non-financial, specific | Declare and participate (all topics discussed were 12 months before he joined the committee) |
Andrew Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | Vertex Pharmaceuticals have provided an unrestricted educational grant to department to fund a one day Cystic Fibrosis meeting in 2016. 04/11/2015 | Non-personal financial, specific | Declare and participate |
Andrew Jones | Adult Physician, Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | Invited to Chair the CF Trust Infection Control Group 01/03/2016 | Specific non-financial personal | No further action necessary. |
Andrew Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | Invited to be a member of the Study Steering Committee of “The cystic fibrosis (CF) anti-staphylococcal antibiotic prophylaxis trial (CF START); a randomised registry trial to assess the safety and efficacy of flucloxacillin as a long term prophylaxis agent for infants with CF”. CF START is a national UK study that has been funded by the HTA. 26/04/2016 | Personal non-financial, specific | Declare and participate |
Andrew Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | Relevant publications RW Lord, AM Jones, A Horsley. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation (0144). Cochrane 2016; 20;1:CD009529. doi: 10.1002/14651858. P Barry, AM Jones. Skin contamination leading to falsely elevated fingerprick tobramycin levels in a patient taking dry powder inhaled tobramycin J Cyst Fibros 2014; 13(6): 754 PJ Barry, AM Jones. New and emerging therapies for cystic fibrosis. Drugs 2015; 75(11):1165–1167 Gilchrist FJ, Belcher J, AM Jones, D Smith, AR Smyth, KW Southern, P Španěl, AK Webb, W Lenney. Exhaled breath hydrogen cyanide as a marker of early Pseudomonas aeruginosa infection. ERJ Open Research 2015; 1 (2) DOI: 10.1183/23120541.00044-2015. Relevant conference abstracts HB Langman, AL Brennan, RJ Bright-Thomas, AM Jones, DW Riley, SC Johnson. Real world´ introduction of tobramycin inhalation powder TIP™ in adults with cystic fibrosis. J Cyst Fibros 2015; 14suppl 1; 165. HB Langman, AL Brennan, RJ Bright-Thomas, AM Jones, DW Riley, SC Johnson. ‘Real world’ experience of introduction of Colobreathe™(Colo) in adults with cystic fibrosis. J Cyst Fibros 2015; 14suppl 1; Ws8.3. 12/09/2016 | Personal non-financial, specific | Declare and participate |
Andrew Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | Invited to be a member of the NHS Specialised Respiratory Clinical Reference Group from August 2016. There is no overlap between this guideline and the work on the reference group. 12/09/2016 | Personal non-financial, specific | Declare and participate |
Andrew Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | A delegate at the UK CF Microbiology Consortium held in Liverpool on 25th November 2016. This meeting received sponsorship from Teva Pharmaceuticals Ltd. I did not receive any personal financial or other incentive in relation to this meeting. 11/01/2017 | Personal non-financial, non-specific | Declare and participate (hospitality within NICE Policy) |
Andy Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | Attended North American CF Conference in October 2016 including a non-promotional event for a large group of CF healthcare professionals sponsored by Chiesi. 23/11/2016 | Personal non-financial, specific | Declare and participate (hospitality was not classed as excessive or extravagant and so within the NICE Policy) |
Andy Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | Attended the Royal Society Medical Meeting (as a delegate) in November 2016. The meeting received an unrestricted educational grant from TEVA. 23/11/2016 | Non-personal financial, non-specific | Declare and participate. |
Andy Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | Attended a meal paid for by Chiesi at the European CF conference in Seville June 2017. This was a meal out with my CF team and teams from all over the UK. There was no promotional talk or activity during the meal. 05/07/2017 | Personal financial, non-specific | |
Andy Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | Speaker at Oxford regional CF meeting June 2017. The meeting receives an educational grant from Teva. I was not paid an honorarium. 05/07/2017 | Non-personal financial, non-specific | |
Andy Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | Sponsorship from Teva for CF Centre’s annual away day team meeting. Teva hired the room for the meeting, this was done directly by Teva and the conference facility and included basic refreshments for all participants, no other payment was received either by myself or the department. 05/07/2017 | Non-personal financial, non-specific | |
Andy Jones | Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust | I attended a one-day meeting in March 2017 for CF centre directors run by the CF Trust to discuss the future of adult CF care. 05/07/2017 | Personal non-financial, non-specific | |
David Lacy | General Paediatrician Wirral University Teaching Hospital NHS Foundation Trust | Attended a meal paid for by Chiesi at the European CF conference in Brussels. This was a meal out with my CF team and teams from all over the UK. There was no promotional talk or activity during the meal. At the rest of the conference there were scientific talks on many different products-these were not sponsored in any way by the drug companies. However I did go to a lunch time talk sponsored by vertex where lunch was provided – Vertex make Ivacaftor which is not being considered in the guideline. 03/03/2015 | Personal non-financial, non-specific Non-specific as this is a hospitality event and therefore not directly discussed in this guideline | Declare and participate (expenses within NICE policy) |
David Lacy | General Paediatrician Wirral University Teaching Hospital NHS Foundation Trust | Attended the Cystic Fibrosis Trust “UK CF Conference” 7th September 2016. This was sponsored by Galapagos a company that are developing drugs targeting the underlying molecular defect in CF. Also attended as part of the conference a talk sponsored by Vertex that make ivacaftor and Orkambi. There were no specific talks that covered areas of the guideline we are developing. 12/09/2016 | Non-personal non-financial, non-specific | Declare and participate |
David Lacy | General Paediatrician Wirral University Teaching Hospital NHS Foundation Trust | Attended European CF conference in Seville (8/06 – 10/06). Attended a meal provided by Chiesi which was attended by many of the UK MDTs and had no promotional component. Attended a lunch time symposium by Vertex. 05/07/2017 | Personal non-financial, non-specific | |
Nichola MacDuff | Adult Specialist Nurse, Advanced Clinical Nurse Specialist & Lead Nurse, Black Country Adult CF Centre, Royal Wolverhampton NHS Trust | Husband is a shareholder in the following companies: GlaxoSmithKline and Lidco. 21/04/2015 | Personal financial, non-specific | Declare and participate |
Nichola MacDuff | Adult Specialist Nurse, Advanced Clinical Nurse Specialist & Lead Nurse, Black Country Adult CF Centre, Royal Wolverhampton NHS Trust | Teaching to GPs on inhaler devices and COPD guidelines sponsored by Astra Zeneca 01/03/2016 | Personal financial, non-specific | Declare and participate (COPD is not within the scope of the guideline) |
Nichola MacDuff | Adult Specialist Nurse, Advanced Clinical Nurse Specialist & Lead Nurse, Black Country Adult CF Centre, Royal Wolverhampton NHS Trust | Attended a Chiesi sponsored dinner while at the European CF Conference in Basel, Switzerland. 26/04/2016 | Personal non-financial, non-specific Non-specific as this is a hospitality event and therefore not directly discussed in this guideline | Declare and participate (expenses within NICE policy) |
Nicola McDuff | Adult Specialist Nurse, Advanced Clinical Nurse Specialist & Lead Nurse, Black Country Adult CF Centre, Royal Wolverhampton NHS Trust | Arranging a “respiratory update day” on Asthma and COPD. Meeting sponsored by GSK who will provide catering only. 05/07/2017 | Non-personal non-financial, non-specific | |
Helen McCabe | Principal Paediatric Dietitian - Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust | Attendance at the European CF meeting in Brussels, received evening hospitality from Pharmaceutical firms (Chiesi, Umedica and Novartis, who make antibiotics used in the treatment of Cystic Fibrosis). 03/06/2015 | Personal non-financial, non-specific | Declare and participate (expenses hospitality within NICE policy) |
Helen McCabe | Principal Paediatric Dietitian - Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust | Contributed to a meeting by Nutricia Advanced Medical Care to discuss paediatric products/developments. 31/09/2015 | Non-personal financial, specific | Declare and participate |
Helen McCabe | Principal Paediatric Dietitian - Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust | Paper published in the Journal of Clinical Nutrition on a multi-centre trial that I was involved in, for a new infant feed produced by the feed company Nutricia. Trial finished in 2014, but just published online in April 2017. 05/07/2017 | Personal non-financial, non-specific | Declare and participate |
Helen McCabe | Principal Paediatric Dietitian - Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust | Currently involved in a follow up evaluation of that feed due the company having to use a new source of protein for the peptides in the feed. A sum of £200 will be paid by Nutricia to the department account for each evaluation. No personal monies will be received. 05/07/2017 | Non-personal financial, non-specific | Declare and participate |
Helen McCabe | Principal Paediatric Dietitian - Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust | Involvement in supporting and producing of a video for education launched at the European CF Conference in June 2017 entitled “Growth in children with CF”. No monies were received, only expenses incurred for travel to Leeds Beckett University to produce the video were reimbursed by the ECFS. 05/07/2017 | Personal non-financial, non-specific | Declare and participate |
Helen Parrott | Physiotherapist, Clinical Specialty Lead, Adult CF Therapies Royal Brompton Hospital | Participated in an advisory board run by Forest Pharmaceuticals on nebuliser devices in 2012. 03/03/2015 | Personal financial, specific | Declare and participate (this occurred more than 12 months before appointment to the committee) |
Helen Parrott | Physiotherapist, Clinical Specialty Lead, Adult CF Therapies Royal Brompton Hospital | Annually attends a professional study day (ACPCF) which is partly sponsored by Forest Laboratories. 03/03/2015 | Personal non-financial, specific | Declare and participate |
Helen Parrott | Physiotherapist, Clinical Specialty Lead, Adult CF Therapies Royal Brompton Hospital | Published articles: Clinical effects of Mannitol in adults with Cystic Fibrosis (co-author, for presentation at the European CF conference, June 2015 in Brussels), Tolerability of inhaled dry powder Mannitol – 1 year follow up (coauthor) for presentation at the European CF conference (June 2015 in Brussels), Inhaled therapy in CF – agents, devices, regimens (co-author, for publication in June issue of Breathe) and ‘Cystic Fibrosis’ (Bilton and Bush, co-author of the physiotherapy chapter due for publication in summer 2015). 03/03/2015 | Personal non-financial, specific | Declare and participate |
Helen Parrott | Physiotherapist, Clinical Specialty Lead, Adult CF Therapies Royal Brompton Hospital | Established and attends a CF Physiotherapy prescribers continuing professional development group which is fully funding by Forest Laboratories. 03/03/2015 | Non-personal financial, specific | Declare and participate |
Helen Parrott | Physiotherapist, Clinical Specialty Lead, Adult CF Therapies Royal Brompton Hospital | Chair of a meeting related to Cystic Fibrosis and the medicines used to treat the condition. Expenses and refreshments were paid for by Forest Laboratories. 21/04/2015 | Personal non-financial, specific | Declare and participate (expenses within NICE policy) |
Helen Parrott | Physiotherapist, Clinical Specialty Lead, Adult CF Therapies Royal Brompton Hospital | Attendance at the European CF conference in Brussels with social events sponsored by Chiesi. 19/08/2015 | Personal non-financial, specific | Declare and participate (expenses within NICE policy) |
Helen Parrott | Physiotherapist, Clinical Specialty Lead, Adult CF Therapies Royal Brompton Hospital | Invited to be involved in an expert panel at the Clinical Advances in CF conference on palliative care for late stage CF. No speaker fee or travel expenses received. 19/08/2015 | Personal non-financial, specific | Declare and participate |
Helen Parrott | Physiotherapist, Clinical Specialty Lead, Adult CF Therapies Royal Brompton Hospital | Advisory board on ‘Adherence’ run by Hammell Communications for Chiesi (no conversations regarding drugs or topics relevant to the guideline were discussed) – consultancy fee of £350 received. 23/11/2016 | Personal financial, non-specific | Advice taken from NICE - Declare and withdraw from future discussions regarding tobramycin and hypertonic saline. |
Helen Parrott | Physiotherapist, Clinical Specialty Lead, Adult CF Therapies Royal Brompton Hospital | British Thoracic Society Winter Meeting Dec 2016 has abstract submitted as a poster with my name as an author which is a survey on the role of the physiotherapy for the CF patient in ITU. 11/01/2017 | Personal non-financial, specific | Declare and participate |
Sarah Popple | Senior Pharmacist Paediatrics and Cystic Fibrosis University Hospitals of Leicester. | Attended Cystic Fibrosis Pharmacists Group study day and educational meeting sponsored by Actavis Pharmaceuticals (Forest Laboratories) manufacturer of Colomycin, which included an educational meeting with lunch provided. 03/03/2015 | Non-personal financial, specific | Declare and participate (expenses within NICE policy) |
Sarah Popple | Senior Pharmacist Paediatrics and Cystic Fibrosis University Hospitals of Leicester. | Invited speaker on Cystic Fibrosis management at parallel study day to NPPG conference for which will receive honorarium paid by Profile Productions. Profile productions are not a Pharma company, they are a corporate company who manage events and organise the NPPG conference. It is a different company to profile who produce promixin. Conference input was general to cystic fibrosis reaching junior pharmacists and those new to paediatrics about cystic fibrosis in a broad sense and covers all medications used. There was no particular focus on any drug other than to discuss current practice. 03/03/2015 | Personal financial, specific | Declare and participate (expenses within NICE policy) |
Sarah Popple | Senior Pharmacist Paediatrics and Cystic Fibrosis University Hospitals of Leicester. | Funding approved from AbbVie pharmaceuticals (Synagis manufacturer – not of significant relevance to Cystic Fibrosis) to attend Neonatal and Paediatric Pharmacists Group Conference November 2015. AbbVie are not relevant to this guideline. 31/09/2015 | Personal financial, non-specific | Declare and participate |
Sarah Popple | Senior Pharmacist Paediatrics and Cystic Fibrosis University Hospitals of Leicester. | Attended a team building event with CF team called ‘better teams together’ a corporate initiative being run by Trust. Participation of team is aiming to improve communication with shared care centre. The event was sponsored by Vertex (Kalydeco/Orkambi) who gave a short presentation at the beginning and funded the room hire, refreshments and a meal. 12/09/2016 | Non-personal, non-financial, non-specific | Declare and participate |
Sarah Popple | Senior Pharmacist Paediatrics and Cystic Fibrosis University Hospitals of Leicester. | Attended a joint meeting between paediatric and adult CF service in Leicester. Meeting venue and refreshments were sponsored by Actavis pharmaceuticals (pulmozyme) followed by a meal afterwards. There was no promotional content to the meeting and nothing specific to this guideline was discussed. 23/11/2016 | Personal non-financial, specific | Declare and participate |
Sarah Popple | Senior Pharmacist Paediatrics and Cystic Fibrosis University Hospitals of Leicester. | Attended the Cystic Fibrosis Pharmacist Group study day in Birmingham Jurys Inn – Day was sponsored by Actavis pharmaceuticals (pulmozyme). The meeting venue and lunch was provided by the sponsors. 23/11/2016 | Personal non-financial, specific | Declare and participate |
Sarah Popple | Senior Pharmacist Paediatrics and Cystic Fibrosis University Hospitals of Leicester. | Invited speaker at Neonatal and Paediatric Pharmacists Group Conference (NPPG) Introduction to Paediatric Pharmaceutical Care study day. Delivered a teaching session on cystic fibrosis to pharmacists new to paediatrics. Organised by profile productions and the conference has various pharmaceutical industry stands but none were relevant to cystic fibrosis. Will receive an honorarium for this. 23/11/2016 | Personal financial, non-specific | Declare and participate |
Sarah Popple | Senior Pharmacist Paediatrics and Cystic Fibrosis University Hospitals of Leicester. | Facilitated a roundtable at the NPPG conference above on ‘New treatments in CF and funding issues in Shared Care’. It covered recent developments in CF care, newly licensed drugs and those still in clinical trials. It did not focus on any one new treatment or any one pharmaceutical company. Nothing sensitive to this guideline was discussed. For this I received one night’s accommodation at the conference venue funded by profile productions. 23/11/2016 | Personal non-financial, specific | Declare and participate (expenses within NICE Policy) |
Sarah Popple | Senior Pharmacist Paediatrics and Cystic Fibrosis University Hospitals of Leicester. | Received sponsorship from Abbvie pharmaceuticals for registration and accommodation for one night at the Neonatal and Paediatric Pharmacists Group conference. Abbvie have no CF interest relevant to this guideline. 23/11/2016 | Personal financial, non-specific | Declare and participate (no relevance to the topics discussed within the CF guideline) |
Sarah Popple | Senior Pharmacist Paediatrics and Cystic Fibrosis University Hospitals of Leicester | New job title Senior Pharmacist Paediatrics and Cystic Fibrosis University Hospitals of Leicester. 05/07/2017 | Personal, non-financial, non-specific | Declare and participate. |
Keith Thompson | Senior Respiratory Pharmacist, Royal Brompton and Harefield NHS Foundation Trust | Manuscript for a service development project on the use of inhaled antibiotics (aztreonam lysine in combination with another agent – tobramycin or colomycin) in people with CF, prescribed within the UK commissioning policy. This work has not been commercially sponsored but he has had access to an independent economic consultant who has been remunerated by Gilead Sciences Inc. Not personally remunerated for this work which was subsequently not published. It was discussed at European CF Conference in May 2015 (Pharmacy meeting only), but has not been referenced in the meeting discussions 03/06/2015 | Personal non-financial, specific | Declare and participate. |
Keith Thompson | Senior Respiratory Pharmacist, Royal Brompton and Harefield NHS Foundation Trust | Reimbursed by Gilead for expenses (Conference fees and accommodation paid directly; travel was reimbursed for personal out of pocket travel expense [£97.50 Eurostar return standard class ticket]) incurred in the attendance of the May 2015 European Cystic Fibrosis conference. Hospitality at said conference from Chiesi Ltd. | Personal non-financial, specific | Declare and participate (expenses within NICE policy) |
Keith Thompson | Senior Respiratory Pharmacist, Royal Brompton and Harefield NHS Foundation Trust | Attendance at annual UKCF Pharmacist Group Steering Committee meeting and study day sponsored by Allergan-Actavis the manufacturer of Colomycin® and Colobreathe®. Standard class travel reimbursed as out of pocket expense (£45.45); overnight accommodation and evening meal in hotel restaurant (without alcohol) covered directly between sponsor and hotel. | Personal non-financial, specific | Declare and participate (expenses within NICE policy) |
Keith Thompson | Senior Respiratory Pharmacist, Royal Brompton and Harefield NHS Foundation Trust | Member of the steering group for the James Lind Alliance Priority Setting Partnership in CF, which has no pharmaceutical industry representation or sponsorship. This project will seek to prioritise research questions in CF in conjunction with the ‘CF community’ | Personal non-financial, specific | Declare and participate |
Keith Thompson | Senior Respiratory Pharmacist, Royal Brompton and Harefield NHS Foundation Trust | As chair of UK CF Pharmacist Group, oversan an update of the CF Trust document ‘Pharmacy Standards of Care’ for CF centres which is a document referred to in the NHS England Service Specification for CF. 26/04/2016 | Personal non-financial, specific | Declare and participate |
Keith Thompson | Senior Respiratory Pharmacist, Royal Brompton and Harefield NHS Foundation Trust | Invitation accepted to update a ‘tab’ entitled ‘Approved and Off-Label drugs for the management of CF in the EU’ in the Hospital Pharmacy Europe Pocket Guide to CF (the previous edition was published in 2013). This contains information on a number of drugs used in CF which will be discussed in the NICE CF guideline, but is limited to collation of information on drug doses taken from manufacturers’ data or relevant literature, rather than review or recommendation. Support for the editorial development of the project was provided by Vertex, manufacturer of Kalydeco® and Orkambi® which are licensed for the treatment of CF but do not fall within the scope of this guideline. Chapter was published; not referenced in guideline; no personal financial interest (honorarium was not offered or accepted). 26/04/2016 | Personal non-financial, specific | Declare and participate. |
Keith Thompson | Senior Respiratory Pharmacist, Royal Brompton and Harefield NHS Foundation Trust | Wrote a manuscript entitled ‘Conventional therapies and emergent precision medicines for cystic fibrosis: challenges and opportunities’ which was published in the Clinical Pharmacist journal (Nov 2016). This was commissioned by the publisher – there was no sponsorship from the pharmaceutical industry, nor remuneration received for the piece. The manuscript was based on published information already in the public domain, and was based on current UK practice and guidance. There was no disclosure of information discussed in the NICE GDG meetings, the main topic (precision medicine) is outside the scope of the current guideline, and the guideline does not reference the manuscript. 11/01/2017 | Personal non-financial, non-specific | Declare and participate |
Martin Walshaw | Consultant Physician in General and Chest Medicine at Royal Liverpool and Broadgreen University Hospitals NHS Trust, and The Liverpool Heart and Chest Hospital NHS Foundation Trust Honorary Professor of Medicine at the University of Liverpool | For the last 5 years, provided patients for clinical trials of potential new therapies from pharmaceutical companies including Vertex, Aptalis, AstraZeneca and AlgiPharma. 03/03/2015 | Non-personal non-financial, specific | Declare and participate |
Martin Walshaw | Consultant Physician in General and Chest Medicine at Royal Liverpool and Broadgreen University Hospitals NHS Trust, and The Liverpool Heart and Chest Hospital NHS Foundation Trust Honorary Professor of Medicine at the University of Liverpool | Speaker at All Wales conference on Cystic Fibrosis sponsored by Avartis. The title of talk was “Cross-infection in CF – Fact and Fantasy” which was an overview of the evidence/lack of evidence for cross infection (mainly for NTM) and gave the options currently available. Avartis sponsored the meeting non-promotionally, but I did not receive any support for travel or speakers fees from them. 21/04/2015 | Personal non-financial, non-specific | Declare and participate (cross infection covered in guideline, but this was general overview of the evidence landscape, particularly for NTM) |
Martin Walshaw | Consultant Physician in General and Chest Medicine at Royal Liverpool and Broadgreen University Hospitals NHS Trust, and The Liverpool Heart and Chest Hospital NHS Foundation Trust Honorary Professor of Medicine at the University of Liverpool | Attendance at the European CF meeting in Brussels, evening hospitality from Pharmaceutical firms (Chiesi, Eumedica and Avartis. 03/06/2015 | Personal non-financial, specific | Declare and participate (hospitality within NICE policy) |
Martin Walshaw | Consultant Physician in General and Chest Medicine at Royal Liverpool and Broadgreen University Hospitals NHS Trust, and The Liverpool Heart and Chest Hospital NHS Foundation Trust Honorary Professor of Medicine at the University of Liverpool | Ongoing role in shaping CF care in England by representing the Mersey Senate area on the Clinical Reference Group. Meeting on – 23/11/15. 26/04/2016 | Personal non-financial, specific | Declare and participate |
Martin Walshaw | Consultant Physician in General and Chest Medicine at Royal Liverpool and Broadgreen University Hospitals NHS Trust, and The Liverpool Heart and Chest Hospital NHS Foundation Trust Honorary Professor of Medicine at the University of Liverpool | Former member of the (now defunct) CF CRG that advised NHSE on CF service specifications including those for the formation of clinical services. 26/04/2016 | Personal non-financial, specific | Declare and participate |
Martin Walshaw | Consultant Physician in General and Chest Medicine at Royal Liverpool and Broadgreen University Hospitals NHS Trust, and The Liverpool Heart and Chest Hospital NHS Foundation Trust Honorary Professor of Medicine at the University of Liverpool | Attended several non-promotional pharmaceutical company sponsored evening meals at the European CF Conference in Basel, as part of large groups of UK CF healthcare professionals. 15/06/2016 | Personal non-financial, specific | Declare and participate (hospitality within NICE policy) |
Martin Walshaw | Consultant Physician in General and Chest Medicine at Royal Liverpool and Broadgreen University Hospitals NHS Trust, and The Liverpool Heart and Chest Hospital NHS Foundation Trust Honorary Professor of Medicine at the University of Liverpool | Was a delegate at the UK CF Microbiology Consortium held in Liverpool on 25th November 2016. This meeting received sponsorship from Teva Pharmaceuticals Ltd. Chaired a meeting during this consortium but the content did not relate to any topics covered in this guideline. No personal financial or other incentive in relation to this meet received. 11/01/2017 | Personal non-financial, non-specific | Declare and participate. |
Martin Walshaw | Consultant Physician in General and Chest Medicine at Royal Liverpool and Broadgreen University Hospitals NHS Trust, and The Liverpool Heart and Chest Hospital NHS Foundation Trust Honorary Professor of Medicine at the University of Liverpool | As Liverpool Adult CF Centre Director attended a one day symposium in Birmingham sponsored by the CF Trust and NHSE Specialist Respiratory CRG. “The future of adult CF care in the UK” Lunch provided No fees or travelling expenses paid. 05/07/2017 | Personal non-financial, non-specific | Declare and participate. |